Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy
Author Information
Author(s): Masood Ashiq, Azmi Asfar S., Mohammad Ramzi M.
Primary Institution: Karmanos Cancer Institute, Wayne State University
Hypothesis
Can small molecule inhibitors of Bcl-2 family proteins improve treatment outcomes for pancreatic cancer?
Conclusion
Small molecule inhibitors targeting Bcl-2 family proteins show promise in overcoming resistance to chemotherapy in pancreatic cancer.
Supporting Evidence
- Pancreatic cancer has a complex etiology and displays a wide range of cellular escape pathways.
- Bcl-2 family proteins are overexpressed in most cancers, including pancreatic cancer.
- Small molecule inhibitors have shown promise in preclinical studies against pancreatic cancer.
Takeaway
This study looks at new drugs that can help kill pancreatic cancer cells by blocking proteins that prevent cell death.
Methodology
The review discusses various small molecule inhibitors of Bcl-2 proteins and their preclinical efficacy against pancreatic cancer.
Limitations
Many trials have been disappointing, and the specific functions of mutations in pancreatic cancer remain unclear.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website